Global Ketorolac Injection Market Growth 2026-2032
Description
The global Ketorolac Injection market size is predicted to grow from US$ 133 million in 2025 to US$ 193 million in 2032; it is expected to grow at a CAGR of 2.8% from 2026 to 2032.
Ketorolac tromethamine injection is a prescription injectable nonsteroidal anti-inflammatory drug (NSAID) for short-term analgesia. Its active ingredient is a salt formed from ketorolac and tromethamine. It exerts its analgesic effect (and also has some anti-inflammatory and antipyretic properties) primarily by inhibiting cyclooxygenase (COX) to reduce prostaglandin production. This drug is typically used for short-term treatment of moderate to severe acute pain (commonly in perioperative or emergency pain management). It is characterized by its strong analgesic effect and reduced need for opioids. However, like other NSAIDs, it carries important safety risks such as gastrointestinal bleeding/ulceration, renal impairment, and bleeding. Therefore, strict control of the course of treatment and dosage is emphasized in clinical practice, and it must be used according to contraindications (such as active gastrointestinal bleeding, severe renal insufficiency, and high perioperative bleeding risk).
The demand for ketorolac tromethamine injection is essentially driven by the scenario of "short-term, intensive analgesia in hospitals." At the label level, it is positioned as a short-term (maximum of 5 days for adults) tool for managing moderate to severe acute pain, achieving "opioid-level analgesia requirements," which aligns particularly well with the clinical pathways for perioperative and emergency acute pain. Simultaneously, the massive number of surgeries performed globally each year and the continuous standardization of perioperative management have made "opioid-free/multimodal analgesia to reduce opioid use" a long-term trend, providing structural support for NSAID-based injectable analgesia. However, the market expansion of this product is naturally limited by its risk profile: the label explicitly emphasizes several important contraindications and warnings, including renal risk, bleeding risk, and contraindication in CABG surgery. Hospital medication management will more strongly constrain its use within the boundaries of "short treatment course, controllable population, and monitorable risk."
From a competitive landscape perspective, ketorolac injection represents a typical combination of a "mature, generic product + high barriers to entry in sterile injectable manufacturing": brand differentiation is limited, with competition primarily focused on sterile production and quality system capabilities, stable supply capabilities, packaging formats, and hospital compliance support (such as single-dose vials, barcodes and hospital dispensing friendliness, and channel coverage). In markets like the US, publicly available data shows that this product is supplied by multiple companies under different NDC/packaging company identities, including large generic injectable platforms (such as Pfizer and Fresenius Kabi) as well as multiple generic drug companies and packaging/distribution entities (such as Sun and Sagent), reflecting a multi-layered supply chain and price competition. For buyers (hospitals/group purchasing), evaluation dimensions often shift from "efficacy differences" to "supply disruption risk, compliance documentation, batch-to-batch consistency, and recall and change control history," which explains why manufacturing and quality management are given greater emphasis in procurement and market access for this type of product.
North America is the largest market, with a share about 40%, followed by Asia-Pacific and Europe with the share about 27% and 20%. In terms of product, 30mg/ml ketorolac injection is the largest segment, with a share over 64%. And in terms of application, the largest application is hospital, followed by clinics.
Future growth is more likely to stem from changes in "clinical pathways and delivery methods" rather than new selling points at the pharmacological level. On the one hand, the strengthening of multimodal analgesia in guidelines and academic consensus will drive hospitals to continuously optimize perioperative analgesia combinations and increase the weighting of non-opioid analgesia. Evidence is also accumulating regarding the effectiveness of NSAIDs in reducing postoperative pain and opioid usage when combined with regional anesthesia and glucocorticoids. On the other hand, safety and compliance requirements will continue to shape the market: the 5-day treatment limit and warnings about bleeding/kidney risk make it more suitable as a short-term tool rather than a long-term medication. Hospitals may place greater emphasis on tiered medication, perioperative bleeding risk management, and kidney function monitoring, thereby prompting companies to invest more in compliance with instructions, risk communication, and real-world medication management support. Meanwhile, given the frequent disruptions to the sterile injectable supply chain, suppliers that can provide more "ready-to-use/less error-prone" packaging specifications and have stable production capacity and consistent quality have a greater chance of gaining an advantage in centralized procurement/hospital access.
LP Information, Inc. (LPI) ' newest research report, the “Ketorolac Injection Industry Forecast” looks at past sales and reviews total world Ketorolac Injection sales in 2025, providing a comprehensive analysis by region and market sector of projected Ketorolac Injection sales for 2026 through 2032. With Ketorolac Injection sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Ketorolac Injection industry.
This Insight Report provides a comprehensive analysis of the global Ketorolac Injection landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Ketorolac Injection portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Ketorolac Injection market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Ketorolac Injection and breaks down the forecast by Concentration, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Ketorolac Injection.
This report presents a comprehensive overview, market shares, and growth opportunities of Ketorolac Injection market by product type, application, key manufacturers and key regions and countries.
Segmentation by Concentration:
15mg/ml
30mg/ml
Segmentation by Application:
Hospital
Clinics
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Pfizer
Fresenius Kabi
Sun Pharmaceutical
Sagent Pharmaceuticals
Baxter
Glenmark Pharmaceutical
Sola Pharmaceutical
TC Pharmaceuticals (Jiangsu) Co., Ltd
Lunan Pharm
Yunnan Longhai Natured Plant Pharmaceutical
Hairon Pharma
Sichuan Medcalo
Chengdu Brilliant Pharmaceuticals
Yung Shin Pharm
Tianjin Chase Sun Pharmaceutical
ZISKA Pharmaceuticals
Key Questions Addressed in this Report
What is the 10-year outlook for the global Ketorolac Injection market?
What factors are driving Ketorolac Injection market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Ketorolac Injection market opportunities vary by end market size?
How does Ketorolac Injection break out by Concentration, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
Ketorolac tromethamine injection is a prescription injectable nonsteroidal anti-inflammatory drug (NSAID) for short-term analgesia. Its active ingredient is a salt formed from ketorolac and tromethamine. It exerts its analgesic effect (and also has some anti-inflammatory and antipyretic properties) primarily by inhibiting cyclooxygenase (COX) to reduce prostaglandin production. This drug is typically used for short-term treatment of moderate to severe acute pain (commonly in perioperative or emergency pain management). It is characterized by its strong analgesic effect and reduced need for opioids. However, like other NSAIDs, it carries important safety risks such as gastrointestinal bleeding/ulceration, renal impairment, and bleeding. Therefore, strict control of the course of treatment and dosage is emphasized in clinical practice, and it must be used according to contraindications (such as active gastrointestinal bleeding, severe renal insufficiency, and high perioperative bleeding risk).
The demand for ketorolac tromethamine injection is essentially driven by the scenario of "short-term, intensive analgesia in hospitals." At the label level, it is positioned as a short-term (maximum of 5 days for adults) tool for managing moderate to severe acute pain, achieving "opioid-level analgesia requirements," which aligns particularly well with the clinical pathways for perioperative and emergency acute pain. Simultaneously, the massive number of surgeries performed globally each year and the continuous standardization of perioperative management have made "opioid-free/multimodal analgesia to reduce opioid use" a long-term trend, providing structural support for NSAID-based injectable analgesia. However, the market expansion of this product is naturally limited by its risk profile: the label explicitly emphasizes several important contraindications and warnings, including renal risk, bleeding risk, and contraindication in CABG surgery. Hospital medication management will more strongly constrain its use within the boundaries of "short treatment course, controllable population, and monitorable risk."
From a competitive landscape perspective, ketorolac injection represents a typical combination of a "mature, generic product + high barriers to entry in sterile injectable manufacturing": brand differentiation is limited, with competition primarily focused on sterile production and quality system capabilities, stable supply capabilities, packaging formats, and hospital compliance support (such as single-dose vials, barcodes and hospital dispensing friendliness, and channel coverage). In markets like the US, publicly available data shows that this product is supplied by multiple companies under different NDC/packaging company identities, including large generic injectable platforms (such as Pfizer and Fresenius Kabi) as well as multiple generic drug companies and packaging/distribution entities (such as Sun and Sagent), reflecting a multi-layered supply chain and price competition. For buyers (hospitals/group purchasing), evaluation dimensions often shift from "efficacy differences" to "supply disruption risk, compliance documentation, batch-to-batch consistency, and recall and change control history," which explains why manufacturing and quality management are given greater emphasis in procurement and market access for this type of product.
North America is the largest market, with a share about 40%, followed by Asia-Pacific and Europe with the share about 27% and 20%. In terms of product, 30mg/ml ketorolac injection is the largest segment, with a share over 64%. And in terms of application, the largest application is hospital, followed by clinics.
Future growth is more likely to stem from changes in "clinical pathways and delivery methods" rather than new selling points at the pharmacological level. On the one hand, the strengthening of multimodal analgesia in guidelines and academic consensus will drive hospitals to continuously optimize perioperative analgesia combinations and increase the weighting of non-opioid analgesia. Evidence is also accumulating regarding the effectiveness of NSAIDs in reducing postoperative pain and opioid usage when combined with regional anesthesia and glucocorticoids. On the other hand, safety and compliance requirements will continue to shape the market: the 5-day treatment limit and warnings about bleeding/kidney risk make it more suitable as a short-term tool rather than a long-term medication. Hospitals may place greater emphasis on tiered medication, perioperative bleeding risk management, and kidney function monitoring, thereby prompting companies to invest more in compliance with instructions, risk communication, and real-world medication management support. Meanwhile, given the frequent disruptions to the sterile injectable supply chain, suppliers that can provide more "ready-to-use/less error-prone" packaging specifications and have stable production capacity and consistent quality have a greater chance of gaining an advantage in centralized procurement/hospital access.
LP Information, Inc. (LPI) ' newest research report, the “Ketorolac Injection Industry Forecast” looks at past sales and reviews total world Ketorolac Injection sales in 2025, providing a comprehensive analysis by region and market sector of projected Ketorolac Injection sales for 2026 through 2032. With Ketorolac Injection sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Ketorolac Injection industry.
This Insight Report provides a comprehensive analysis of the global Ketorolac Injection landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Ketorolac Injection portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Ketorolac Injection market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Ketorolac Injection and breaks down the forecast by Concentration, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Ketorolac Injection.
This report presents a comprehensive overview, market shares, and growth opportunities of Ketorolac Injection market by product type, application, key manufacturers and key regions and countries.
Segmentation by Concentration:
15mg/ml
30mg/ml
Segmentation by Application:
Hospital
Clinics
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Pfizer
Fresenius Kabi
Sun Pharmaceutical
Sagent Pharmaceuticals
Baxter
Glenmark Pharmaceutical
Sola Pharmaceutical
TC Pharmaceuticals (Jiangsu) Co., Ltd
Lunan Pharm
Yunnan Longhai Natured Plant Pharmaceutical
Hairon Pharma
Sichuan Medcalo
Chengdu Brilliant Pharmaceuticals
Yung Shin Pharm
Tianjin Chase Sun Pharmaceutical
ZISKA Pharmaceuticals
Key Questions Addressed in this Report
What is the 10-year outlook for the global Ketorolac Injection market?
What factors are driving Ketorolac Injection market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Ketorolac Injection market opportunities vary by end market size?
How does Ketorolac Injection break out by Concentration, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
137 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 2 Executive Summary
- 3 Global by Company
- 4 World Historic Review for Ketorolac Injection by Geographic Region
- 5 Americas
- 6 APAC
- 7 Europe
- 8 Middle East & Africa
- 9 Market Drivers, Challenges and Trends
- 10 Manufacturing Cost Structure Analysis
- 11 Marketing, Distributors and Customer
- 12 World Forecast Review for Ketorolac Injection by Geographic Region
- 13 Key Players Analysis
- 14 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
